Literature DB >> 31992104

Fisetin Improved Rotenone-Induced Behavioral Deficits, Oxidative Changes, and Mitochondrial Dysfunctions in Rat Model of Parkinson's Disease.

Kanakalatha Alikatte1, Suresh Palle2, Jadi Rajendra Kumar3, Naveen Pathakala3.   

Abstract

Oxidative stress plays an important role in the pathogenesis of Parkinson's disease (PD), particularly the inhibition of mitochondrial complex-I. This study aimed to evaluate the effect of fisetin in the rotenone-induced rat model of PD. Rotenone was administered (2   mg/kg s.c.) for 35   days to induce PD in animals. Fisetin was administered at two doses (10   mg/kg and 20   mg/kg p.o.) for 25   days to the animals that were given rotenone. Behavioral experiment, i.e. cylinder test, was performed to assess the motor asymmetry. Animals were euthanized, and mid brains were isolated for the estimation of tricarboxylic acid cycle enzymes, oxidative measures (lipid peroxidation (LPO), glutathione (GSH) and catalase) and complex-I activity. In addition, histopathological studies were conducted. Fisetin treatment improved motor function in the cylinder test and reversed the rotenone-induced changes in mitochondrial enzymes, striatal dopamine levels, antioxidant enzyme levels and histological changes. An important finding of this study was both the doses of fisetin significantly (p   <   0.05) enhanced rotenone-induced behavioral and biochemical changes and the effects were found to be dose dependent. Based on the present results, we hypothesize that fisetin may improve the mitochondrial enzyme activity, thereby preventing the pathogenesis of PD.

Entities:  

Keywords:  Parkinson’s disease; complex I; oxidative stress; rotenone

Year:  2020        PMID: 31992104     DOI: 10.1080/19390211.2019.1710646

Source DB:  PubMed          Journal:  J Diet Suppl        ISSN: 1939-0211


  4 in total

Review 1.  Preventing and Treating Neurological Disorders with the Flavonol Fisetin.

Authors:  Pamela Maher
Journal:  Brain Plast       Date:  2021-02-09

2.  Rotenone aggravates PD-like pathology in A53T mutant human α-synuclein transgenic mice in an age-dependent manner.

Authors:  An-Di Chen; Jia-Xin Cao; Hai-Chao Chen; Hong-Li Du; Xiao-Xia Xi; Jing Sun; Jie Yin; Yu-Hong Jing; Li-Ping Gao
Journal:  Front Aging Neurosci       Date:  2022-08-08       Impact factor: 5.702

Review 3.  Natural products targeting mitochondria: emerging therapeutics for age-associated neurological disorders.

Authors:  Zhibin Liang; Antonio Currais; David Soriano-Castell; David Schubert; Pamela Maher
Journal:  Pharmacol Ther       Date:  2020-11-20       Impact factor: 12.310

Review 4.  Recent Neurotherapeutic Strategies to Promote Healthy Brain Aging: Are we there yet?

Authors:  Chul-Kyu Kim; Perminder S Sachdev; Nady Braidy
Journal:  Aging Dis       Date:  2022-02-01       Impact factor: 6.745

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.